Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Vaccine targeting SIVmac251 protease cleavage sites protects macaques against vaginal infection
Journal of Clinical Investigation, Volume 130, No. 12, Year 2020
Notification
URL copied to clipboard!
Description
After over 3 decades of research, an effective anti-HIV vaccine remains elusive. The recently halted HVTN702 clinical trial not only further stresses the challenge to develop an effective HIV vaccine but also emphasizes that unconventional and novel vaccine strategies are urgently needed. Here, we report that a vaccine focusing the immune response on the sequences surrounding the 12 viral protease cleavage sites (PCSs) provided greater than 80% protection to Mauritian cynomolgus macaques against repeated intravaginal SIVmac251 challenges. The PCS-specific T cell responses correlated with vaccine efficacy. The PCS vaccine did not induce immune activation or inflammation known to be associated with increased susceptibility to HIV infection. Machine learning analyses revealed that the immune microenvironment generated by the PCS vaccine was predictive of vaccine efficacy. Our study demonstrates, for the first time to our knowledge, that a vaccine which targets only viral maturation, but lacks full-length Env and Gag immunogens, can prevent intravaginal infection in a stringent macaque/SIV challenge model. Targeting HIV maturation thus offers a potentially novel approach to developing an effective HIV vaccine. © 2020, American Society for Clinical Investigation.
Available Materials
https://efashare.b-cdn.net/share/pmc/articles/PMC7685735/bin/jci-130-138728-s186.pdf
Authors & Co-Authors
Omange, Robert Were
Canada, Winnipeg
University of Manitoba
Liang, Binhua B.
Canada, Ottawa
Public Health Agency of Canada
Canada, Winnipeg
University of Manitoba
Lim, Soyon
United States, Boston
Beth Israel Deaconess Medical Center
Li, Lin
Canada, Ottawa
Public Health Agency of Canada
Kashem, Mohammad Abul
Canada, Winnipeg
University of Manitoba
Seaman, Michael S.
United States, Boston
Beth Israel Deaconess Medical Center
Balshaw, Robert F.
Canada, Winnipeg
University of Manitoba
Li, Qingsheng
United States, Lincoln
University of Nebraska–lincoln
Alonso Fernández, María José
Spain, Santiago de Compostela
Universidad de Santiago de Compostela
Plummer, Francis Allan
Canada, Winnipeg
University of Manitoba
Canada, Ottawa
Public Health Agency of Canada
Whitney, James B.
United States, Boston
Beth Israel Deaconess Medical Center
United States, Boston
Massachusetts General Hospital
Luo, Ma
Canada, Winnipeg
University of Manitoba
Canada, Ottawa
Public Health Agency of Canada
Statistics
Citations: 5
Authors: 12
Affiliations: 7
Identifiers
Doi:
10.1172/JCI138728
ISSN:
00219738
Research Areas
Infectious Diseases